皮肤科接受免疫调节剂和生物制剂治疗的患者接种 SARS-CoV-2（COVID-19）疫苗：来自澳大利亚皮肤医学学会的建议。
SARS-CoV-2 (COVID-19) vaccination in dermatology patients on immunomodulatory and biologic agents: Recommendations from the Australasian Medical Dermatology Group.
机构信息
Skin Health Institute, Carlton, Victoria, Australia.
Waikato Clinical Campus, Faculty of Medical and Health Sciences, University of Auckland, Hamilton, New Zealand.
出版信息
Australas J Dermatol. 2021 May;62(2):151-156. doi: 10.1111/ajd.13593. Epub 2021 Mar 30.
Abstract
As the phase III COVID-19 vaccine trials excluded patients on immunosuppressive treatments, or patients with significant autoimmunity, the Australasian Medical Dermatology Group make the following preliminary recommendations around COVID-19 vaccination in dermatology patients on immunomodulatory and/or biologic agents. Vaccination against COVID-19 is strongly encouraged for all patients on immunomodulatory drugs and/or biologic agents. There are currently insufficient data to recommend one COVID-19 vaccine or vaccine type (mRNA, recombinant, inactivated virus) over another. No specific additional risk in patients on immunomodulatory or biologic therapies has so far been identified. Data on vaccine efficacy in patients on immunomodulatory or biologic therapies are missing, so standard vaccination protocols are recommended until otherwise advised.
摘要
由于 COVID-19 三期疫苗试验将正在接受免疫抑制治疗的患者或患有严重自身免疫性疾病的患者排除在外，因此澳大拉西亚医学皮肤病学组就皮肤科正在接受免疫调节剂和/或生物制剂治疗的患者接种 COVID-19 疫苗提出以下初步建议。强烈鼓励所有接受免疫调节剂药物和/或生物制剂治疗的患者接种 COVID-19 疫苗。目前尚无足够数据推荐一种 COVID-19 疫苗或疫苗类型（mRNA、重组、灭活病毒）优于另一种。迄今为止，尚未发现正在接受免疫调节剂或生物疗法治疗的患者有特定的额外风险。在接受免疫调节剂或生物疗法治疗的患者中，疫苗有效性的数据缺失，因此建议在接到进一步通知之前，推荐使用标准疫苗接种方案。
相似文献
1
SARS-CoV-2 (COVID-19) vaccination in dermatology patients on immunomodulatory and biologic agents: Recommendations from the Australasian Medical Dermatology Group.皮肤科接受免疫调节剂和生物制剂治疗的患者接种 SARS-CoV-2（COVID-19）疫苗：来自澳大利亚皮肤医学学会的建议。
Australas J Dermatol. 2021 May;62(2):151-156. doi: 10.1111/ajd.13593. Epub 2021 Mar 30.
2
An evidence-based guide to SARS-CoV-2 vaccination of patients on immunotherapies in dermatology.皮肤科接受免疫治疗患者的 SARS-CoV-2 疫苗接种的循证指南。
J Am Acad Dermatol. 2021 Jun;84(6):1652-1666. doi: 10.1016/j.jaad.2021.01.047. Epub 2021 Jan 19.
3
A randomized, double-blind, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of SARS-CoV-2 vaccine (inactivated, Vero cell): a structured summary of a study protocol for a randomised controlled trial.一项评估 SARS-CoV-2 疫苗（灭活，Vero 细胞）有效性和安全性的随机、双盲、安慰剂对照 III 期临床试验：一项随机对照试验研究方案的结构化总结。
Trials. 2021 Apr 13;22(1):276. doi: 10.1186/s13063-021-05180-1.
4
COVID-19 vaccine safety and efficacy in patients with immune-mediated inflammatory disease: Review of available evidence.COVID-19 疫苗在免疫介导的炎症性疾病患者中的安全性和有效性：现有证据综述。
J Am Acad Dermatol. 2021 Nov;85(5):1274-1284. doi: 10.1016/j.jaad.2021.07.054. Epub 2021 Aug 4.
5
COVID vaccine recommendations in dermatologic patients on immunosuppressive agents: Lessons learned from pandemic.皮肤科免疫抑制患者的 COVID 疫苗推荐：大流行期间的经验教训。
J Cosmet Dermatol. 2022 Dec;21(12):6568-6573. doi: 10.1111/jocd.15448. Epub 2022 Dec 12.
6
SARS-CoV-2 vaccination and practical points in psoriasis patients: A narrative review.SARS-CoV-2 疫苗接种与银屑病患者的实际问题：叙述性综述。
Dermatol Ther. 2022 May;35(5):e15430. doi: 10.1111/dth.15430. Epub 2022 Mar 22.
7
Dermatology patients on biologics and certain other systemic therapies should receive a "booster" messenger RNA COVID-19 vaccine dose: A critical appraisal of recent Food and Drug Administration and Advisory Committee on Immunization Practices recommendations.接受生物制剂和某些其他全身治疗的皮肤科患者应接种一剂信使核糖核酸新冠病毒“加强针”疫苗：对美国食品药品监督管理局和免疫实践咨询委员会近期建议的批判性评估
J Am Acad Dermatol. 2021 Nov;85(5):1113-1116. doi: 10.1016/j.jaad.2021.08.031. Epub 2021 Aug 23.
8
Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.一项在 18-59 岁健康成年人中进行的新型冠状病毒灭活疫苗的安全性、耐受性和免疫原性的随机、双盲、安慰剂对照、1/2 期临床试验。
Lancet Infect Dis. 2021 Feb;21(2):181-192. doi: 10.1016/S1473-3099(20)30843-4. Epub 2020 Nov 17.
9
Safety and immunogenicity of a recombinant tandem-repeat dimeric RBD-based protein subunit vaccine (ZF2001) against COVID-19 in adults: two randomised, double-blind, placebo-controlled, phase 1 and 2 trials.一种基于重组串联重复二聚体 RBD 的蛋白亚单位疫苗（ZF2001）在成年人中的安全性和免疫原性：两项随机、双盲、安慰剂对照、1 期和 2 期临床试验。
Lancet Infect Dis. 2021 Aug;21(8):1107-1119. doi: 10.1016/S1473-3099(21)00127-4. Epub 2021 Mar 24.
10
COVID-19 vaccination rate and willingness of an additional dose among inflammatory bowel disease patients receiving biologic therapy: Fearless and with desire.炎症性肠病患者接受生物治疗时对 COVID-19 疫苗接种率和追加剂量的意愿：无畏且渴望。
Gastroenterol Hepatol. 2023 Apr;46(4):255-260. doi: 10.1016/j.gastrohep.2022.05.009. Epub 2022 May 21.
引用本文的文献
1
Immunosuppressants in dermatology on vaccine immunogenicity: a prospective cohort study of pemphigus patients in the pandemic.皮肤科免疫抑制剂对疫苗免疫原性的影响：一项关于大流行期间天疱疮患者的前瞻性队列研究。
Front Immunol. 2024 Nov 22;15:1506962. doi: 10.3389/fimmu.2024.1506962. eCollection 2024.
2
A critical review of COVID-19 course and vaccination in dermatology patients on immunomodulatory/biologic therapy: recommendations should not differ between non-pregnant and pregnant individuals.对接受免疫调节/生物治疗的皮肤科患者的COVID-19病程和疫苗接种的批判性综述：非孕妇和孕妇的建议不应有所不同。
Front Med (Lausanne). 2023 Jun 2;10:1121025. doi: 10.3389/fmed.2023.1121025. eCollection 2023.
3
Occurrence of erythema multiforme following COVID-19 vaccination: a review.新型冠状病毒肺炎疫苗接种后多形红斑的发生情况：一项综述
Clin Exp Vaccine Res. 2023 Apr;12(2):87-96. doi: 10.7774/cevr.2023.12.2.87. Epub 2023 Apr 30.
4
Evidence-Based Guidelines for SARS-COV-2 Vaccination of Patients of Skin Allergic Diseases and Patients on Immuno-Therapeutics.皮肤过敏性疾病患者和免疫治疗患者的SARS-CoV-2疫苗接种循证指南。
Indian J Dermatol. 2022 May-Jun;67(3):314. doi: 10.4103/ijd.ijd_440_21.
5
COVID vaccine recommendations in dermatologic patients on immunosuppressive agents: Lessons learned from pandemic.皮肤科免疫抑制患者的 COVID 疫苗推荐：大流行期间的经验教训。
J Cosmet Dermatol. 2022 Dec;21(12):6568-6573. doi: 10.1111/jocd.15448. Epub 2022 Dec 12.
6
A systematic review on mucocutaneous presentations after COVID-19 vaccination and expert recommendations about vaccination of important immune-mediated dermatologic disorders.一项关于 COVID-19 疫苗接种后黏膜皮肤表现的系统评价和关于重要免疫介导性皮肤病疫苗接种的专家建议。
Dermatol Ther. 2022 Jun;35(6):e15461. doi: 10.1111/dth.15461. Epub 2022 Apr 11.
7
Erythema multiforme in COVID-19 patients and following COVID-19 vaccination: manifestations, associations and outcomes.新型冠状病毒肺炎患者及接种新型冠状病毒疫苗后的多形红斑：表现、关联因素及转归
J Eur Acad Dermatol Venereol. 2022 Jul;36(7):e524-e530. doi: 10.1111/jdv.18063. Epub 2022 Mar 21.
8
Recommendations for COVID Vaccination for Dermatological Patients on Immunosuppressive/Immunomodulatory Therapy (IADVL Academy).免疫抑制/免疫调节治疗的皮肤病患者的新冠疫苗接种建议（国际皮肤性病学联盟学会）
Indian Dermatol Online J. 2021 Nov 25;12(Suppl 1):S4-S11. doi: 10.4103/idoj.idoj_412_21. eCollection 2021 Nov.
9
Biologics for Psoriasis During the COVID-19 Pandemic.新冠疫情期间用于治疗银屑病的生物制剂
Front Med (Lausanne). 2021 Dec 6;8:759568. doi: 10.3389/fmed.2021.759568. eCollection 2021.
10
Recurrent herpes zoster after COVID-19 vaccination in patients with chronic urticaria being treated with cyclosporine-A report of 3 cases.3例接受环孢素治疗的慢性荨麻疹患者在接种新冠疫苗后发生复发性带状疱疹——病例报告
J Cosmet Dermatol. 2021 Nov;20(11):3384-3386. doi: 10.1111/jocd.14437. Epub 2021 Sep 12.
本文引用的文献
1
2
SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement.炎症性肠病患者的 SARS-CoV-2 疫苗接种：英国胃肠病学会炎症性肠病分会和 IBD 临床研究小组立场声明。
Lancet Gastroenterol Hepatol. 2021 Mar;6(3):218-224. doi: 10.1016/S2468-1253(21)00024-8. Epub 2021 Jan 26.
3
Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine.mRNA-1273 新型冠状病毒疫苗的有效性和安全性。
N Engl J Med. 2021 Feb 4;384(5):403-416. doi: 10.1056/NEJMoa2035389. Epub 2020 Dec 30.
4
Maintaining Safety with SARS-CoV-2 Vaccines.通过新冠病毒疫苗维持安全性。
N Engl J Med. 2021 Feb 18;384(7):643-649. doi: 10.1056/NEJMra2035343. Epub 2020 Dec 30.
5
Immune Response to Vaccination in Patients with Psoriasis Treated with Systemic Therapies.接受全身治疗的银屑病患者对疫苗接种的免疫反应。
Vaccines (Basel). 2020 Dec 16;8(4):769. doi: 10.3390/vaccines8040769.
6
Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: an interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK.ChAdOx1 nCoV-19 疫苗（阿斯利康）对 SARS-CoV-2 的安全性和有效性：巴西、南非和英国四项随机对照试验的中期分析。
Lancet. 2021 Jan 9;397(10269):99-111. doi: 10.1016/S0140-6736(20)32661-1. Epub 2020 Dec 8.
7
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine.BNT162b2 mRNA 新冠病毒疫苗的安全性和有效性。
N Engl J Med. 2020 Dec 31;383(27):2603-2615. doi: 10.1056/NEJMoa2034577. Epub 2020 Dec 10.
8
Incidence of severe COVID-19 outcomes in psoriatic patients treated with systemic therapies during the pandemic: A Biobadaderm cohort analysis.大流行期间接受系统治疗的银屑病患者中重症 COVID-19 结局的发生率：一项 Biobadaderm 队列分析。
J Am Acad Dermatol. 2021 Feb;84(2):513-517. doi: 10.1016/j.jaad.2020.10.046. Epub 2020 Oct 26.
9
Impact of Hydroxychloroquine on Antibody Responses to the SARS-CoV-2 Coronavirus.羟氯喹对严重急性呼吸综合征冠状病毒2（SARS-CoV-2）抗体反应的影响
Front Immunol. 2020 Aug 4;11:1739. doi: 10.3389/fimmu.2020.01739. eCollection 2020.
10
Covid-19 in Immune-Mediated Inflammatory Diseases - Case Series from New York.免疫介导性炎症疾病中的新冠病毒病——来自纽约的病例系列
N Engl J Med. 2020 Jul 2;383(1):85-88. doi: 10.1056/NEJMc2009567. Epub 2020 Apr 29.
Zotero 插件